March 5, 2024 – Talk Bio

NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns

1 year ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Coverage rejection, Daiichi Sankyo, Enhertu, Health Services, National, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Technology

NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)

Sandoz Wins Historic FDA Approval for First Two Interchangeable Denosumab Biosimilars Targeting Amgen’s Blockbuster Bone Therapy

1 year ago talkbio0Tagged amgen, Approved, Biosimilars, Cancer-related skeletal events, denosumab, interchangeable, Jubbonti, Osteoporosis, patent litigation, Prolia, sandoz, Secondary malignant neoplasm of bone, United States Food and Drug Administration, Wyost, Xgeva

Sandoz, FDA approval, Denosumab biosimilars, Wyost, Jubbonti, Interchangeable, Prolia, Xgeva, Amgen, Osteoporosis, Bone metastases, Cancer-related skeletal events, Patent litigation

Second Positive Phase 2 Trial Boosts Confidence in Alnylam’s RNAi Blood Pressure Med, Supporting Roche’s $2.8 Billion Biobucks Bet

1 year ago talkbio0Tagged Alnylam, blood pressure medication, Hypertension therapy, KARDIA-2, milestone payments, Partnership, RNA Interference, Roche (company), Systolic blood pressure reduction, Zilebesiran

Alnylam RNAi blood pressure medication, Zilebesiran, Phase 2 trial success, Systolic blood pressure reduction, Roche partnership, $2.8 billion milestone payments, Hypertension therapy, KARDIA-2 study

Novo Nordisk’s Ozempic Shows Promising Kidney Benefits for Diabetic Patients

1 year ago talkbio0Tagged Cardiovascular system, Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent, Expanded use, FLOW trial, Ozempic, Novo Nordisk, Reduced risk, semaglutide

Ozempic, Novo Nordisk, Chronic kidney disease, Cardiovascular events, Expanded use, Semaglutide, FLOW trial, Reduced risk, Type 2 diabetes

Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership

1 year ago talkbio0Tagged C4 Therapeutics, Collaboration, Low-Double Digit Tiered Royalties, Merck KGaA, mid-single, Milestone, oncogenic proteins, Targeted Protein Degradation, TORPEDO® Platform, upfront payment

Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million